Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (181-190 of 215) with videos related to

Pageof 22
Sort By:
Blood Advances|August 8, 2023
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapiesEdward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Blood|June 24, 2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesTamer E Fandy, James G Herman, Patrick Kerns, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Blood Advances|October 9, 2020
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentationsSimone Feurstein, Ayodeji Adegunsoye, Danijela Mojsilovic, et al.
Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.
Pageof 22

Showing results (181-190 of 215) with videos related to

Sort By:
Pageof 22
Blood Advances|August 8, 2023
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapiesEdward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Blood|June 24, 2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesTamer E Fandy, James G Herman, Patrick Kerns, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Blood Advances|October 9, 2020
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentationsSimone Feurstein, Ayodeji Adegunsoye, Danijela Mojsilovic, et al.
Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.
Pageof 22